Latest Commercialisation News

Advanced Health Intelligence Ltd (AHI) has secured USD 4 million in convertible debt funding and launched two new commercial partnerships in Canada and the UK, marking significant progress despite its ongoing ASX trading suspension.

High Peak Royalties reported robust cash receipts and successfully repaid its Macquarie Bank facility in the December 2024 quarter, while advancing its geothermal exploration strategy in South Australia.

Nanoveu Limited reports strong momentum in its EyeFly3D technology with a significant purchase order and launches an AI-powered app, while advancing its strategic acquisition of semiconductor innovator EMASS.

Cadoux Limited reports significant progress in its high purity alumina and Minhub rare earths projects, alongside robust environmental, social, and governance initiatives.

Recce Pharmaceuticals has gained key regulatory and ethics approvals for its Phase 3 clinical trial in Indonesia and completed patient dosing for its Phase II trial, while securing a substantial A$6.75 million R&D tax rebate to bolster its financial position.

Cardiex Limited reported a $2.94 million cash outflow for Q2 FY2025 but bolstered its balance sheet with a $3.25 million placement. The company has begun delivering its CONNEQT Pulse units, signaling a new revenue stream and ongoing R&D investment.

Challenger Gold has secured a binding toll processing agreement to fast-track production at its Hualilan Gold Project in Argentina, while also reporting promising drilling results from its Colorado V project in Ecuador and completing a strategic capital raise.

Dreadnought Resources reports robust exploration results including high-grade gold at Mangaroon and niobium at Gifford Creek, alongside new joint ventures and asset sales that position the company for growth.

Pursuit Minerals has reported a remarkable 339% increase in lithium resources at its Rio Grande Sur project in Argentina, alongside plans to commence lithium carbonate production by Q1 2025. The company is also actively pursuing acquisitions and reviewing its gold assets amid tight cost controls.

Purifloh Limited has made significant progress in its PFAS destruction technology, securing a $100,000 BRII feasibility grant while navigating challenges to resume trading on the ASX.

Cleo Diagnostics reports steady progress in its U.S. and Australian clinical trials for an ovarian cancer blood test, maintaining a solid cash reserve of A$7.3 million as it prepares for FDA submission.

Alexium International Group reports a 16% sales increase in Q2 FY25 despite ongoing mattress market softness, driven by strategic product diversification and supply chain improvements.